Using 68Ga-MY6349 PETCT to Detect Trop-2 Expression in Solid Tumors Compared to 18F-FDG PETCT

What this Trial Is About

Researchers are evaluating a new imaging method using 68Ga-MY6349 PETCT to detect Trop-2 expression in tumor lesions of patients with solid tumors. This study aims to compare the effectiveness of this new PET radiotracer with the standard 18F-FDG PETCT imaging to identify patients who may benefit from Trop-2 targeted imaging. The study is observational and involves patients with various types of malignant tumors, either newly diagnosed or previously treated. Participants receive a single intravenous injection of the 68Ga-MY6349 tracer and then undergo PETCT imaging within a set timeframe. They also undergo standard-of-care imaging with 18F-FDG PETCT either for initial assessment or to detect tumor recurrence. The uptake of the tracer in tumors is measured by the maximum standard uptake value SUVmax and compared visually to the standard imaging results. During the study, researchers will assess the feasibility of using 68Ga-MY6349 PETCT for non-invasive evaluation of Trop-2 expression in tumors. Participants will have both imaging tests and their tumor lesions will be documented and analyzed. The primary focus is on imaging accuracy and tracer uptake within one week. This study is sponsored by The First Affiliated Hospital of Xiamen University and involves adults aged 18 years or older with solid tumors.

68Ga-MY6349 PET/CT in Solid Tumors